Multivariable competing risk regression model for LP
| Characteristic . | HR . | 95% CI . | P . |
|---|---|---|---|
| Nodal status | |||
| Nodal | — | — | |
| Extranodal | 0.57 | 0.28-1.16 | .12 |
| Both | 0.72 | 0.17-3.30 | .7 |
| Pre-VLDRT lesion size (cm) | |||
| 0-6 | — | — | |
| ≥6 | 4.69 | 1.75-12.62 | .002 |
| Intent of VLDRT | |||
| Non-curable | — | — | |
| Potentially curable | 0.73 | 0.17-3.11 | .7 |
| Previous No. of lines of systemic therapy | |||
| 0 | — | — | |
| 1 | 1.76 | 0.54-5.77 | .3 |
| 2-4 | 1.71 | 0.53-5.51 | .4 |
| > 4 | 1.15 | 0.11-12.04 | >.9 |
| Previous rituximab | 1.04 | 0.39-2.76 | >.9 |
| Stage at VLDRT | |||
| Limited | — | — | |
| Advanced | 0.78 | 0.35-1.75 | .6 |
| Best overall response | |||
| CR | |||
| PR, SD, or PD | 2.32 | 1.05-5.09 | .036 |
| Characteristic . | HR . | 95% CI . | P . |
|---|---|---|---|
| Nodal status | |||
| Nodal | — | — | |
| Extranodal | 0.57 | 0.28-1.16 | .12 |
| Both | 0.72 | 0.17-3.30 | .7 |
| Pre-VLDRT lesion size (cm) | |||
| 0-6 | — | — | |
| ≥6 | 4.69 | 1.75-12.62 | .002 |
| Intent of VLDRT | |||
| Non-curable | — | — | |
| Potentially curable | 0.73 | 0.17-3.11 | .7 |
| Previous No. of lines of systemic therapy | |||
| 0 | — | — | |
| 1 | 1.76 | 0.54-5.77 | .3 |
| 2-4 | 1.71 | 0.53-5.51 | .4 |
| > 4 | 1.15 | 0.11-12.04 | >.9 |
| Previous rituximab | 1.04 | 0.39-2.76 | >.9 |
| Stage at VLDRT | |||
| Limited | — | — | |
| Advanced | 0.78 | 0.35-1.75 | .6 |
| Best overall response | |||
| CR | |||
| PR, SD, or PD | 2.32 | 1.05-5.09 | .036 |